A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Equities researchers at Zacks Research issued their Q3 2024 earnings per share (EPS) estimates for shares of Eli Lilly and ...

Older Singapore investors can opt for ETFs in Singapore dollars (SGD) listed on the Singapore Exchange S68 The MooSummit took ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Thousands may now be at risk of mold-related illnesses following this year's hurricanes in the American South.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.